每经AI快讯，2月3日，华东医药（000963）(000963.SZ)公告称，全资子公司中美华东收到国家药品监 督管理局签发的《受理通知书》，罗氟司特乳膏(ZORYVE)0.05%上市许可申请获得受理，申报适应症 为适用于2岁至5岁轻度至中度特应性皮炎患者的局部外用治疗。该药物是中美华东与美国Arcutis Biotherapeutics,Inc.合作引进的创新皮肤外用制剂产品，中美华东拥有在大中华区及东南亚的独家权 益。罗氟司特乳膏0.05%相比传统治疗手段有安全性优势，且可用于所有部位，每日一次给药，提高治 疗依从性。该产品研发进程中的重要里程碑，将提升公司在自免皮肤治疗领域的核心竞争力。但药品审 评审批时间、审批结果及未来市场竞争形势存在不确定性。 ...

公司始终坚持"时间领先、技术领先"的经营理念。本次建德工厂原料药生产线通过GMP符合性检查， 再次印证公司具备领先的生产及质量管理体系，对建德工厂创新药CDMO业务从高级中间体向原料药价 值延伸具有里程碑意义，对公司持续开拓创新药原料药客户具有积极意义。 格隆汇2月3日丨ST诺泰（维权）(688076.SH)公布，公司全资子公司杭州澳赛诺生物科技有限公司（以 下简称"澳赛诺"或"建德工厂"）于近日收到浙江省药品监督管理局签发的《药品GMP符合性检查告知 书》（编号：浙2026第0013号），澳赛诺奥格特韦钠原料药正式通过GMP符合性检查。 ...

Core Viewpoint - The company *ST Jingfeng has received a civil ruling from the Intermediate People's Court of Changde City, Hunan Province, approving the reorganization plan and terminating the reorganization process [1] Group 1 - The court's decision is based on the approval of the reorganization plan for Hunan Jingfeng Pharmaceutical Co., Ltd [1] - The termination of the reorganization process indicates a significant development in the company's financial restructuring efforts [1]

Core Viewpoint - The A-share market is expected to enter a slow bull phase in 2025, with major indices significantly rising. As the annual report preview window approaches in early 2026, institutional investors are likely to focus on stocks with long-term growth potential and valuation revaluation space [2][3]. Group 1: Target Price Insights from Citic Securities - Citic Securities has identified 12 stocks with a target price increase of over 50%, indicating a recovery in market confidence. The focus is on sectors that can articulate a logical recovery narrative, particularly in consumer and real estate chains [2][3]. - Among the stocks covered, the highest target price increase is for Baili Tianheng, with a target price of 1322 CNY compared to a closing price of 269.69 CNY, representing a potential upside of 390.19% [3][4]. Group 2: Target Price Insights from Huatai Securities - Huatai Securities has identified 15 stocks with a target price increase of over 50%, focusing on sectors with sustainable recovery capabilities, particularly in price increase chains, high-end manufacturing, and AI [5][6]. - The highest target price increase is for Tianci Materials, with a target price of 80.5 CNY compared to a closing price of 40.04 CNY, indicating a potential upside of 101.05% [6]. Group 3: Target Price Insights from Guotai Junan - Guotai Junan has identified 13 stocks with a target price increase of over 50%, with China Railway leading at a target price of 9.07 CNY against a closing price of 5.37 CNY, representing a potential upside of 68.90% [8][9]. - The firm emphasizes the long-term potential of the "transformation bull" market, supported by improved regulatory governance and economic transformation [8]. Group 4: Target Price Insights from GF Securities - GF Securities has identified three stocks with significant target price increases, including Pudong Development Bank with a target price of 15.65 CNY compared to a closing price of 10.06 CNY, indicating a potential upside of 55.57% [10][11]. - The firm anticipates a strong seasonal market effect during the spring, particularly around the Chinese New Year [10]. Group 5: Target Price Insights from Guotai Securities - Guotai Securities has identified three stocks with target price increases over 50%, including Betta Pharmaceuticals with a target price of 71.95 CNY against a closing price of 45.70 CNY, representing a potential upside of 57.44% [13][15]. - The firm highlights the importance of technology and overseas expansion as key drivers for future growth [13]. Group 6: Target Price Insights from Dongwu Securities - Dongwu Securities has identified three stocks with the highest target price increases, including Tianci Materials with a target price of 79.20 CNY compared to a closing price of 40.40 CNY, indicating a potential upside of 97.80% [19][20]. - The firm expects a strong performance in the market as it transitions towards technology and cyclical sectors [19]. Group 7: Target Price Insights from Guojin Securities - Guojin Securities has identified China Pacific Insurance as the only stock with a target price increase over 50%, with a target price of 73.18 CNY against a closing price of 44.36 CNY, representing a potential upside of 64.97% [16][18]. - The firm believes that the insurance sector is entering a new cycle of growth driven by both volume and price increases [16].

*ST景峰公告，重整计划将以景峰医药现有股本8.8亿股为基数，按照每10股转增10股的比例实施资本公 积金转增股本，共计可转增8.8亿股股票。转增后，景峰医药总股本将增至17.6亿股。前述转增的8.8亿 股股票不再向原股东分配，全部用于引入重整投资人，并由重整投资人提供资金认购，相应资金用于根 据重整计划的规定支付破产费用、清偿各类债务、补充公司流动资金等。 ...

近日，广生堂发布公告称，预计2025年度归母净利润亏损约为1.7亿元至2.4亿元，扣除非经常性损益后的净利润预计 亏损约为1.77亿元至2.48亿元。 公告中提到，业绩亏损的主要原因包括持续的研发投入以及前期固定资产投资较大，导致研发费用和管理费用保持在 较高水平。此外，预计非经常性损益对公司归母净利润的影响约为750万元，同比减少约3573万元，主要因政府补助 大幅减少。 （广生堂公告） ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Insights - The approval of Lurcatinib cream marks a significant opportunity in the vitiligo market, being the first and only targeted therapy approved in China for this condition [7] - Clinical trials have shown positive results, with a significant percentage of patients achieving at least a 75% improvement in facial vitiligo area score after 24 weeks of treatment [7] - The company is also pursuing additional indications for Lurcatinib cream, including atopic dermatitis, which could further enhance its market potential [7] Financial Forecast and Valuation - Revenue projections for the company are as follows: 2023: 8,013 million RMB, 2024: 7,469 million RMB, 2025: 8,166 million RMB, 2026: 9,628 million RMB, and 2027: 12,069 million RMB, with growth rates of -12.4%, -6.8%, 9.3%, 17.9%, and 25.4% respectively [6] - Net profit forecasts are: 2023: 2,401 million RMB, 2024: 1,620 million RMB, 2025: 1,681 million RMB, 2026: 1,942 million RMB, and 2027: 2,333 million RMB, with growth rates of -26.3%, -32.5%, 3.8%, 15.6%, and 20.1% respectively [6] - The estimated reasonable market value for the company in 2026 is 677 billion HKD, based on a combination of price-to-earnings and price-to-sales ratios [7]

Market Performance - The chemical pharmaceutical sector increased by 1.41% on February 3, with Yiming Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 4067.74, up 1.29%, while the Shenzhen Component Index closed at 14127.1, up 2.19% [1] Top Gainers in Chemical Pharmaceutical Sector - Yiming Pharmaceutical (002826) closed at 20.98, up 9.27% with a trading volume of 269,200 shares and a transaction value of 559 million [1] - Yuandong Biological (688513) closed at 68.90, up 8.85% with a trading volume of 64,600 shares [1] - Nami Technology (688690) closed at 29.00, up 7.01% with a trading volume of 93,900 shares and a transaction value of 265 million [1] - Lianhuan Pharmaceutical (600513) closed at 20.15, up 5.94% with a trading volume of 162,200 shares and a transaction value of 323 million [1] Top Losers in Chemical Pharmaceutical Sector - Shuangbi Pharmaceutical (002038) closed at 6.41, down 7.10% with a trading volume of 801,300 shares and a transaction value of 511 million [2] - Haizhi Pharmaceutical (002653) closed at 47.50, down 5.47% with a trading volume of 90,200 shares and a transaction value of 430 million [2] - Nuo Cheng Jianhua (688428) closed at 21.13, down 3.78% with a trading volume of 163,500 shares [2] Capital Flow Analysis - The chemical pharmaceutical sector experienced a net outflow of 42.01 million from institutional investors, while retail investors saw a net inflow of 651 million [2] - The main capital inflow was observed in Yiming Pharmaceutical with 58.98 million, while it faced a net outflow of 58.77 million from retail investors [3] - Other notable inflows included Guangsheng Tang (300436) with 14.8 million from main capital, while it faced a net outflow of 95.56 million from retail investors [3]

Core Viewpoint - The company Shanghai Yizhong expects to achieve a revenue of 317 million yuan in 2025, representing an increase of 82.72%, and a net profit attributable to shareholders of 64.13 million yuan, reflecting a growth of 819.42% [1] Group 1: Revenue and Profit Growth - The projected revenue growth is primarily driven by the inclusion of the core product, paclitaxel micelles, in the national medical insurance catalog [1] - The expected net profit growth is significantly influenced by the company's ongoing investment in research and development, which is advancing multiple innovative drug projects [1] Group 2: Cost Management and Efficiency - The company has implemented refined management of sales and administrative expenses, achieving reasonable spending and effective control [1] - This approach has allowed the company to maintain substantial research and development investments while simultaneously reducing costs and increasing efficiency, leading to significant year-on-year growth in revenue and operating profit [1]

Core Viewpoint - The company and its subsidiaries have been granted a patent for an invention related to carbonyl reductase mutants and their applications, which is expected to enhance technological innovation and core competitiveness, although it will not have a significant impact on production and operations [1] Group 1 - The patent granted is for the invention titled "Carbonyl Reductase Mutant and Its Preparation Method, Application, and Preparation Method of ®-6-Hydroxy-8-Chlorooctanoic Acid Ethyl Ester" [1] - The patent number is ZL202211709938.1, with a validity period of 20 years [1] - The official announcement date of the patent is January 30, 2026 [1] Group 2 - The patent is expected to contribute to technological innovation within the company [1] - The patent will enhance the company's core competitiveness in the industry [1] - The company does not anticipate any major impact on its production and operations from this patent [1]